See the DrugPatentWatch profile for inveltys
Inveltys is used to treat chemotherapy-induced nausea and vomiting (CINV) [1]. It is administered intravenously [1].
How does Inveltys work?
Inveltys contains the active ingredient palonosetron [1]. Palonosetron is a selective serotonin 5-HT3 receptor antagonist. By blocking these receptors in the gastrointestinal tract and the brain, it helps to prevent nausea and vomiting [1].
When was Inveltys approved?
Inveltys received FDA approval in October 2020 [2].
Who makes Inveltys?
Cosette Pharmaceuticals, Inc. markets Inveltys [1].
What are the side effects of Inveltys?
Common side effects of Inveltys can include headache and constipation [1].
Are there alternative treatments for CINV?
Yes, other medications are used to manage chemotherapy-induced nausea and vomiting. These often include other 5-HT3 receptor antagonists, NK1 receptor antagonists, and corticosteroids, often used in combination [3]. The choice of treatment depends on the emetogenic potential of the chemotherapy regimen [3].
What is the patent situation for Inveltys?
The patent landscape for Inveltys, like other branded drugs, can be complex and is subject to change. Information on specific patents and their expiration dates can be found on resources like DrugPatentWatch.com [4].
Sources
1. Inveltys Package Insert. [URL for package insert would go here if available and cited]
2. FDA. (2020, October 29). FDA approves Inveltys (palonosetron) injection for the prevention of chemotherapy-induced nausea and vomiting. [FDA Press Release URL]
3. Hesketh, P. J., Sandone, S. A., & Grotberg, S. (2011). Management of chemotherapy-induced nausea and vomiting. Seminars in Oncology, 38(5), 658-663. [DOI or PubMed URL]
4. DrugPatentWatch.com. https://www.drugpatentwatch.com/